Display Settings:


Send to:

Choose Destination
Am J Surg. 2006 Mar;191(3):305-10.

A multicenter trial of sentinel lymph node mapping in colorectal cancer: prognostic implications for nodal staging and recurrence.

Author information

  • 1McLaren Regional Medical Center, Michigan State University, 3500 Calkins Road, Suite A, Flint, MI 48532, USA. ssahadr@aol.com

Erratum in

  • Am J Surg. 2009 Jul;198(1):156. Seghal, Rajesh [corrected to Sehgal, Rajesh].



Sentinel lymph node (SLN) mapping (M) for staging in colorectal cancer (CRCa) remains controversial and needs to be validated. This study analyzes results of SLNM at a multi-institutional level for CRCa.


Group A patients underwent SLNM with 1 to 3 mL of 1% lymphazurin. First 1 to 4 blue lymph nodes were designated as SLNs and had focused analysis. Group B had standard resection and nodal staging. Patients with a minimum of 2 years of follow-up were analyzed for recurrence.


Overall nodal metastasis were 50% for 500 group A patients versus 35% for 368 group B patients. In SLNM patients success, accuracy, sensitivity, and negative predictability values were 98%, 96%, 90%, and 93%, respectively. With a 2-year minimum follow-up, 153 group A patients had 7% recurrences compared with 25% in 162 group B patients.


SLNM is highly feasible and accurate for staging CRCa with higher detection of nodal metastasis and lower recurrences.

Comment in

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk